Efficacy and safety analysis of D-TACE combined with lenvatinib in the treatment of hepatocellular carcinoma refractory to C-TACE
For patients with cTACE-refractory unresectable HCC, D-TACE combined with lenvatinib demonstrates superior efficacy compared to cTACE plus lenvatinib, with significantly improved ORR, DCR, PFS, and OS, and a comparable safety profile. This combination represents an effective and safe treatment strategy for this challenging patient population.
Authors
- Xiangwen Xia (ORCID: https://orcid.org/0000-0002-5798-1909)
- Chuansheng Zheng (ORCID: https://orcid.org/0000-0002-2435-1417)
- Bin Liang (ORCID: https://orcid.org/0000-0002-6130-8629)
- Haohao Lu (ORCID: https://orcid.org/0000-0002-8470-750X)
Institutions
- Precision for Medicine (United States) (US)
- State Key Laboratory of Information Engineering in Surveying Mapping and Remote Sensing (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
- Hubei University (CN)
Publication Details
- Journal
- BMC Gastroenterology
- Published
- 2025-11-19
- DOI
- https://doi.org/10.1186/s12876-025-04419-4
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00